MCID: MSN004
MIFTS: 37

Mesenchymal Cell Neoplasm

Categories: Cancer diseases

Aliases & Classifications for Mesenchymal Cell Neoplasm

MalaCards integrated aliases for Mesenchymal Cell Neoplasm:

Name: Mesenchymal Cell Neoplasm 12 15 73
Benign Miscellaneous Mesenchymal Tumor 12
Mesenchymal Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3350
NCIt 50 C6587 C7059

Summaries for Mesenchymal Cell Neoplasm

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic connective tissue that is capable of developing into connective tissue, such as bone, and cartilage, the lymphatic system, and the circulatory system.

MalaCards based summary : Mesenchymal Cell Neoplasm, also known as benign miscellaneous mesenchymal tumor, is related to carney triad and gastrointestinal stromal tumor. An important gene associated with Mesenchymal Cell Neoplasm is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and p70S6K Signaling. The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include bone and liver, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Mesenchymal Cell Neoplasm

Diseases related to Mesenchymal Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 131)
# Related Disease Score Top Affiliating Genes
1 carney triad 32.0 KIT PDGFRA
2 gastrointestinal stromal tumor 31.7 CD34 KIT PDGFRA
3 malignant mesenchymoma 31.6 EWSR1 KIT MYOD1
4 gallbladder sarcoma 30.8 CD34 KIT MYOD1
5 inflammatory myofibroblastic tumor 30.1 ALK CLTC KIT RANBP2 TPM3 TPM4
6 rhabdomyosarcoma 28.4 ALK EWSR1 MYOD1 PDGFRA
7 histiocytoma 28.1 ALK EWSR1 KIT MYOD1
8 mediastinal mesenchymal tumor 12.0
9 oncogenic osteomalacia 11.3
10 vaginal carcinosarcoma 11.1
11 ovarian carcinosarcoma 11.1
12 central nervous system mesenchymal non-meningothelial tumor 10.9
13 fetal lung interstitial tumor 10.9
14 paraganglioma and gastric stromal sarcoma 10.9
15 myoma 10.9
16 reticular perineurioma 10.8 KIT PDGFRA
17 sm-ahnmd 10.7 KIT PDGFRA
18 desmoid tumor 10.7 KIT PDGFRA
19 sarcomatoid renal cell carcinoma 10.7 KIT PDGFRA
20 pediatric fibrosarcoma 10.6 CLTC TPM3
21 endometrial small cell carcinoma 10.6 KIT PDGFRA
22 pulmonary vein stenosis 10.6 KIT PDGFRA
23 hypereosinophilic syndrome, idiopathic 10.6 KIT PDGFRA
24 gallbladder leiomyoma 10.6 CD34 KIT
25 lung leiomyosarcoma 10.6 CD34 KIT
26 lung adenoid cystic carcinoma 10.6 ALK KIT PDGFRA
27 pleomorphic carcinoma 10.5 ALK KIT
28 liver leiomyoma 10.5 CD34 KIT
29 deep leiomyoma 10.5 CD34 KIT
30 neurilemmoma 10.5 KIT PDGFRA SMARCB1
31 extracutaneous mastocytoma 10.5 CD34 KIT
32 undifferentiated pleomorphic sarcoma 10.5 KIT PDGFRA
33 small intestine leiomyosarcoma 10.5 CD34 KIT
34 small intestinal sarcoma 10.5 CD34 KIT
35 prostate leiomyosarcoma 10.5 CD34 KIT
36 malignant peripheral nerve sheath tumor 10.5 KIT PDGFRA SMARCB1
37 chronic eosinophilic leukemia 10.5 KIT PDGFRA TPM3
38 diffuse cutaneous mastocytosis 10.4 CD34 KIT
39 sarcomatoid squamous cell skin carcinoma 10.4 CD34 KIT
40 ovary sarcoma 10.4 CD34 HBA1
41 ovarian angiosarcoma 10.4 CD34 HBA1
42 pediatric angiosarcoma 10.4 CD34 HBA1
43 thyroid angiosarcoma 10.4 CD34 HBA1
44 heart sarcoma 10.4 KIT PDGFRA
45 neurogenic arthropathy 10.4 CD34 HBA1
46 plexiform schwannoma 10.4 CD34 KIT
47 spleen angiosarcoma 10.4 CD34 HBA1
48 thyroid sarcoma 10.4 CD34 HBA1
49 hobnail hemangioma 10.4 CD34 HBA1
50 glomeruloid hemangioma 10.3 CD34 HBA1

Graphical network of the top 20 diseases related to Mesenchymal Cell Neoplasm:



Diseases related to Mesenchymal Cell Neoplasm

Symptoms & Phenotypes for Mesenchymal Cell Neoplasm

GenomeRNAi Phenotypes related to Mesenchymal Cell Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.53 PDGFRA
2 Decreased viability GR00221-A-1 9.53 ALK KIT PDGFRA SMARCB1
3 Decreased viability GR00221-A-2 9.53 SMARCB1
4 Decreased viability GR00221-A-3 9.53 PDGFRA SMARCB1
5 Decreased viability GR00221-A-4 9.53 ALK PDGFRA
6 Decreased viability GR00301-A 9.53 KIT
7 Decreased viability GR00381-A-1 9.53 SMARCB1
8 Decreased viability GR00402-S-2 9.53 ALK KIT PDGFRA SMARCB1

MGI Mouse Phenotypes related to Mesenchymal Cell Neoplasm:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 ALK CD34 KIT MYOD1 PDGFRA SMARCB1

Drugs & Therapeutics for Mesenchymal Cell Neoplasm

Drugs for Mesenchymal Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
3 Adjuvants, Anesthesia Phase 3
4 Analgesics Phase 3
5 Analgesics, Opioid Phase 3
6 Anesthetics Phase 3,Phase 2
7 Anesthetics, General Phase 3
8 Anesthetics, Intravenous Phase 3
9 Central Nervous System Depressants Phase 3
10 Liver Extracts Phase 3
11 Narcotics Phase 3
12 Peripheral Nervous System Agents Phase 3
13 Cola Nutraceutical Phase 3
14
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
15
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
16
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
17
Dactinomycin Approved, Investigational Phase 2 50-76-0 2019 457193
18
Epirubicin Approved Phase 2 56420-45-2 41867
19
Etoposide Approved Phase 2 33419-42-0 36462
20
Ifosfamide Approved Phase 2 3778-73-2 3690
21
Lenograstim Approved, Investigational Phase 2 135968-09-1
22
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
23
Ponatinib Approved, Investigational Phase 2 943319-70-8 24826799
24
Nintedanib Approved Phase 2 656247-17-5 56843413
25
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
26
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
27
Doxil Approved June 1999 Phase 2 31703
28 Mitogens Phase 2
29 Anti-Bacterial Agents Phase 2
30 Antibiotics, Antitubercular Phase 2
31 Topoisomerase Inhibitors Phase 2
32 Alkylating Agents Phase 2
33 Anti-Infective Agents Phase 2,Phase 1
34 Antimitotic Agents Phase 2
35 Antineoplastic Agents, Alkylating Phase 2
36 Antineoplastic Agents, Phytogenic Phase 2
37 Antirheumatic Agents Phase 2
38 Etoposide phosphate Phase 2
39 Immunosuppressive Agents Phase 2,Phase 1
40
Isophosphamide mustard Phase 2 0
41 Nucleic Acid Synthesis Inhibitors Phase 2
42 Imatinib Mesylate Phase 2 220127-57-1 123596
43 Protein Kinase Inhibitors Phase 2
44 PONATINIB  Phase 2
45 Antibodies Phase 1, Phase 2
46 Antibodies, Blocking Phase 1, Phase 2
47 Antimetabolites Phase 1, Phase 2
48 Antimetabolites, Antineoplastic Phase 1, Phase 2
49 Antiviral Agents Phase 1, Phase 2
50 Immunoglobulins Phase 1, Phase 2

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
3 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 High-Dose Proton/Photon RT + Surgery of Sarcomas of the Thoracic, Lumbar Spine/Sacrum Completed NCT00592345 Phase 1, Phase 2
5 Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) Completed NCT01172548 Phase 2 imatinib mesylate
6 A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed NCT01874665 Phase 2 Ponatinib
7 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
8 Vorinostat (SAHA) in Uterine Sarcoma Recruiting NCT03509207 Phase 2 Vorinostat Oral Capsule
9 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
10 Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) Recruiting NCT03109301 Phase 2 Selumetinib (AZD6244 hyd sulfate)
11 Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors Active, not recruiting NCT02015065 Phase 2 Vandetanib
12 BGJ398 for the Treatment of Tumor-Induced Osteomalacia Not yet recruiting NCT03510455 Phase 2 BGJ398
13 Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore) Withdrawn NCT02766842 Phase 2
14 Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma Completed NCT01460901 Phase 1
15 NHS-IL12 for Solid Tumors Recruiting NCT01417546 Phase 1 NHS-IL-12
16 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia Unknown status NCT01524016 Early Phase 1 68Ga-DOTATATE
17 Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia Unknown status NCT01660308
18 Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia Completed NCT00099762
19 Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors Completed NCT02884154 Not Applicable
20 the Laparoscopic and Endoscopic Cooperative Surgery of Gastrointestinal Stromal Tumor Recruiting NCT02763748 Not Applicable
21 The Clinical Relevance of Immune Cells and CTC in HNSCC Patients Recruiting NCT02420600
22 Doppler Ultrasound in Characterization of Superficial Soft Tissue Masses Not yet recruiting NCT03171857

Search NIH Clinical Center for Mesenchymal Cell Neoplasm

Genetic Tests for Mesenchymal Cell Neoplasm

Anatomical Context for Mesenchymal Cell Neoplasm

MalaCards organs/tissues related to Mesenchymal Cell Neoplasm:

41
Bone, Liver

Publications for Mesenchymal Cell Neoplasm

Articles related to Mesenchymal Cell Neoplasm:

# Title Authors Year
1
A spontaneous mesenchymal cell neoplasm in the adult newt, Diemictylus viridescens. ( 5104322 )
1971

Variations for Mesenchymal Cell Neoplasm

Expression for Mesenchymal Cell Neoplasm

Search GEO for disease gene expression data for Mesenchymal Cell Neoplasm.

Pathways for Mesenchymal Cell Neoplasm

GO Terms for Mesenchymal Cell Neoplasm

Cellular components related to Mesenchymal Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.13 ALK KIT PDGFRA
2 muscle thin filament tropomyosin GO:0005862 8.62 TPM3 TPM4

Biological processes related to Mesenchymal Cell Neoplasm according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.85 ALK FGF23 KIT MYOD1 PDGFRA SMARCB1
2 MAPK cascade GO:0000165 9.73 FGF19 FGF23 KIT PDGFRA
3 protein autophosphorylation GO:0046777 9.69 ALK KIT PDGFRA
4 positive regulation of MAPK cascade GO:0043410 9.67 ALK KIT PDGFRA
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.65 ALK KIT PDGFRA
6 negative regulation of signal transduction GO:0009968 9.63 ALK KIT PDGFRA
7 peptidyl-tyrosine phosphorylation GO:0018108 9.56 ALK FGF23 KIT PDGFRA
8 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.52 KIT PDGFRA
9 positive regulation of kinase activity GO:0033674 9.5 ALK KIT PDGFRA
10 positive regulation of protein kinase B signaling GO:0051897 9.46 FGF19 FGF23 KIT PDGFRA
11 positive regulation of phospholipase C activity GO:0010863 9.4 KIT PDGFRA
12 phosphatidylinositol phosphorylation GO:0046854 9.26 FGF19 FGF23 KIT PDGFRA
13 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.02 ALK FGF19 FGF23 KIT PDGFRA

Molecular functions related to Mesenchymal Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAP kinase kinase kinase activity GO:0004709 9.54 ALK KIT PDGFRA
2 mitogen-activated protein kinase kinase binding GO:0031434 9.5 ALK KIT PDGFRA
3 protein tyrosine kinase activity GO:0004713 9.46 ALK FGF23 KIT PDGFRA
4 fibroblast growth factor receptor binding GO:0005104 9.43 FGF19 FGF23
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 ALK KIT PDGFRA
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.26 FGF19 FGF23 KIT PDGFRA
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.92 FGF19 FGF23 KIT PDGFRA
8 protein binding GO:0005515 10.22 ALK CLTC EWSR1 FGF19 FGF23 HBA1

Sources for Mesenchymal Cell Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....